Future Oncology

Abbr. FUTURE ONCOL ·ENGLAND ·Frequency Monthly ·Avg. articles/yr 192 articles

2.6

Latest IF

2.50%

Self-citation

Submission difficulty

偏慢,4 - 8周

Review cycle

About Journal

Future Oncology是一本国际同行评审期刊，ISSN号为1479-6694，由英国Future Medicine Ltd出版，出版地为英国，出版周期为月刊。该杂志的影响因子根据年份有所不同，最新数据需查阅Journal Citation Reports。它属于非开放获取（非OA）期刊，被SCI收录，中科院分区情况需参考最新分区表。杂志专注于肿瘤学领域的前沿研究，涵盖肿瘤生物学、临床治疗、转化医学和个性化医疗等方向，尤其关注新兴疗法和肿瘤治疗的未来发展趋势。其发文特点包括发表原创研究、综述和专家观点，注重多学科交叉研究。杂志质量较高，审稿流程严格，但需注意其影响因子波动可能反映竞争激烈的肿瘤学领域动态，投稿前建议核实最新学术评价和分区信息以规避潜在风险。

IF Trend

Recent Articles

Is neoadjuvant therapy redefining the surgeon’s role in melanoma? 2026-09-24

Review of evidence and future directions following the TUBA study: a long-term prospective preference study comparing risk-reducing salpingectomy with delayed oophorectomy to salpingo-oophorectomy 2026-09-23

Beyond survival: advancing psycho-oncology research on fear of recurrence or progression 2026-09-23

First-line management of unresectable hepatocellular carcinoma: clinical perspectives from the CheckMate 9DW study 2026-09-22

A patient’s experience with follicular lymphoma from diagnosis to cure: the life-changing impact of CAR T-cell therapy 2026-09-22

Plain language summary of the RELATIVITY-098 study results: nivolumab plus relatlimab given after melanoma is removed by surgery 2026-09-22

The role of contrast enhanced ct plus pan-immune-inflammation value in predicting outcomes of hepatocellular carcinoma after hepatectomy 2026-09-21

Translating avelumab maintenance into clinical practice: nationwide outcomes in Czech patients with advanced or metastatic urothelial carcinoma 2026-09-21

Efficacy of anlotinib plus immune checkpoint inhibitors in soft-tissue sarcoma: systematic review and meta-analysis 2026-09-19

MH-Penile-002: a phase II, prospective, single-arm trial of neoadjuvant anti-EGFR antibody-drug conjugate plus PD-1 inhibitor in penile cancer with challenging penile preservation or regional lymph node metastasis 2026-09-18